Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Jul;62(1):118–121. doi: 10.1038/bjc.1990.241

Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status.

P Masson 1, B Pålsson 1, A Andrén-Sandberg 1
PMCID: PMC1971719  PMID: 2390470

Abstract

Monoclonal antibodies 19-9 and C-50 were used to assay the cancer associated tumour antigens CA 19-9 and CA-50 in plasma from patients with confirmed pancreatic cancer, and related to the blood group and Lewis blood cell status. The plasma expressions of CA 19-9 or CA-50 were similar, including cases where the patients had Lewis phenotype Le (a-b-). However, analyses of both the tumour antigens could be used to differentiate the presence of cancer from its absence in Le (a-b-) individuals. The findings indicate that the targets for the monoclonal antibodies 19-9 and C-50 are similar. The practical implications of these findings are discussed.

Full text

PDF
118

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dienst C., Clodius T., Oldörp T., Uhlenbruck G., Diehl V. CA 19-9, CA 50 und CEA bei Pankreas- und Gastrointestinaltumoren. Vergleichende Untersuchungen. Med Klin (Munich) 1987 Jan 30;82(2):45–50. [PubMed] [Google Scholar]
  2. GRUBB R. Observations on the human group system Lewis. Acta Pathol Microbiol Scand. 1951;28(1):61–81. doi: 10.1111/j.1699-0463.1951.tb05004.x. [DOI] [PubMed] [Google Scholar]
  3. Haglund C., Kuusela P., Jalanko H., Roberts P. J. Serum CA 50 as a tumor marker in pancreatic cancer: a comparison with CA 19-9. Int J Cancer. 1987 Apr 15;39(4):477–481. doi: 10.1002/ijc.2910390412. [DOI] [PubMed] [Google Scholar]
  4. Haglund C., Lindgren J., Roberts P. J., Nordling S. Tissue expression of the tumor marker CA 50 in benign and malignant pancreatic lesions. A comparison with CA 19-9. Int J Cancer. 1986 Dec 15;38(6):841–846. doi: 10.1002/ijc.2910380610. [DOI] [PubMed] [Google Scholar]
  5. Heptner G., Domschke S., Schneider M. U., Siegfried W., Domschke W. Vergleich der Tumormarker CA 50 und CA 19-9 bei benignen und malignen Erkrankungen des oberen Gastrointestinaltraktes. Dtsch Med Wochenschr. 1986 Mar 7;111(10):374–378. doi: 10.1055/s-2008-1068458. [DOI] [PubMed] [Google Scholar]
  6. Kannagi R., Levery S. B., Hakomori S. Lea-active heptaglycosylceramide, a hybrid of type 1 and type 2 chain, and the pattern of glycolipids with Lea, Leb, X (Lex), and Y (Ley) determinants in human blood cell membranes (ghosts). Evidence that type 2 chain can elongate repetitively but type 1 chain cannot. J Biol Chem. 1985 May 25;260(10):6410–6415. [PubMed] [Google Scholar]
  7. Koprowski H., Steplewski Z., Mitchell K., Herlyn M., Herlyn D., Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979 Nov;5(6):957–971. doi: 10.1007/BF01542654. [DOI] [PubMed] [Google Scholar]
  8. Lindholm L., Holmgren J., Svennerholm L., Fredman P., Nilsson O., Persson B., Myrvold H., Lagergård T. Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides. Int Arch Allergy Appl Immunol. 1983;71(2):178–181. doi: 10.1159/000233384. [DOI] [PubMed] [Google Scholar]
  9. Magnani J. L., Nilsson B., Brockhaus M., Zopf D., Steplewski Z., Koprowski H., Ginsburg V. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem. 1982 Dec 10;257(23):14365–14369. [PubMed] [Google Scholar]
  10. Marr A. M., Donald A. S., Watkins W. M., Morgan W. T. Molecular and genetic aspects of human blood-group Le-b specificity. Nature. 1967 Sep 23;215(5108):1345–1349. doi: 10.1038/2151345a0. [DOI] [PubMed] [Google Scholar]
  11. Masson P., Pålsson B., Andren-Sandberg A. CA-50 in patients with pancreatic disease--an evaluation of three different laboratory techniques. Scand J Clin Lab Invest. 1988 Dec;48(8):751–755. doi: 10.3109/00365518809088756. [DOI] [PubMed] [Google Scholar]
  12. Mäkelä O., Mäkelä P. H., Kortekangas A. In vitro transformation of the Lewis blood groups of erythrocytes. Ann Med Exp Biol Fenn. 1967;45(2):159–164. [PubMed] [Google Scholar]
  13. Månsson J. E., Fredman P., Nilsson O., Lindholm L., Holmgren J., Svennerholm L. Chemical structure of carcinoma ganglioside antigens defined by monoclonal antibody C-50 and some allied gangliosides of human pancreatic adenocarcinoma. Biochim Biophys Acta. 1985 Mar 27;834(1):110–117. doi: 10.1016/0005-2760(85)90182-1. [DOI] [PubMed] [Google Scholar]
  14. Nilsson O., Lindholm L., Holmgren J., Svennerholm L. Monoclonal antibodies raised against NeuAc alpha 2-6neolactotetraosylceramide detect carcinoma-associated gangliosides. Biochim Biophys Acta. 1985 Jul 31;835(3):577–583. doi: 10.1016/0005-2760(85)90127-4. [DOI] [PubMed] [Google Scholar]
  15. Pour P. M., Tempero M. M., Takasaki H., Uchida E., Takiyama Y., Burnett D. A., Steplewski Z. Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in pancreatic cancer cells in comparison with the patient's blood group type. Cancer Res. 1988 Oct 1;48(19):5422–5426. [PubMed] [Google Scholar]
  16. Schwenk J., Makovitzky J. Tissue expression of the cancer-associated antigens CA 19-9 and CA-50 in chronic pancreatitis and pancreatic carcinoma. Int J Pancreatol. 1989 Jul;5(1):85–98. doi: 10.1007/BF02925701. [DOI] [PubMed] [Google Scholar]
  17. WATKINS W. M., MORGAN W. T. Possible genetical pathways for the biosynthesis of blood group mucopolysaccharides. Vox Sang. 1959 Apr;4(2):97–119. doi: 10.1111/j.1423-0410.1959.tb04023.x. [DOI] [PubMed] [Google Scholar]
  18. Watkins W. M. Blood-group substances. Science. 1966 Apr 8;152(3719):172–181. doi: 10.1126/science.152.3719.172. [DOI] [PubMed] [Google Scholar]
  19. Yazawa S., Asao T., Izawa H., Miyamoto Y., Matta K. L. The presence of CA19-9 in serum and saliva from Lewis blood-group negative cancer patients. Jpn J Cancer Res. 1988 Apr;79(4):538–543. doi: 10.1111/j.1349-7006.1988.tb01624.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES